Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. - Wikidata - awgldk - TriplyDB

Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.

Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.

http://www.wikidata.org/entity/Q34694716

about

Recent progress in pancreatic cancer Pancreatic Cancer Genetics Inherited pancreatic cancer syndromes High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families Switching off malignant mesothelioma: exploiting the hypoxic microenvironment Genetic predisposition to pancreatic cancer.High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.Rare presentations of primary melanoma and special populations: a systematic review.Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers Preferences Regarding Return of Genomic Results to Relatives of Research Participants, Including after Participant Death: Empirical Results from a Cancer Biobank.Return of Genetic Research Results to Participants and Families: IRB Perspectives and Roles ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors.Genomic sequencing of key genes in mouse pancreatic cancer cells.Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the TTD group.Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy.Clinical applications of melanoma genetics.Metabolomics in pancreatic cancer biomarkers research.Team work and cytopathology molecular diagnosis of solid pancreatic lesions.Genetics of pancreatic cancer and implications for therapy.CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts Familial pancreatic cancer Novel nano-drug combination therapeutic regimen demonstrates significant efficacy in the transgenic mouse model of pancreatic ductal adenocarcinoma

P2860

Q24626346-B0AE6570-08B5-49D0-8CC0-4B600C754FB9 Q26765235-8078B2EA-8742-49AF-B12B-B2AA1E605185 Q26853530-D2E639DF-623D-4C89-B00A-D29EBC5BC0AD Q28242124-C1605FBD-F48A-45BD-B8EE-13AAE66C35DF Q29248727-F796C409-2866-478A-9F82-A6D120216BE0 Q34067868-F1987E0A-C639-496C-AFEE-F9C8C4CAD77D Q34452269-0560247B-82CC-4217-85B5-AB7742957950 Q34602917-4E6EA009-7C16-48E0-B20D-3A2CCE413DC5 Q35147046-3B7FC39B-D715-434F-AB77-64AE6FA0F537 Q35213835-7AE0CF2D-6658-4256-9680-F9519FCBE513 Q35630278-EB0BA834-F8F7-4E21-BD0E-5AD18B3220D0 Q36047747-0A1B513B-D9C4-4991-8CED-8E85ABA61296 Q36197062-2DA6F1C8-3E10-48D0-B34C-0A8C57621550 Q36198371-DAC28507-E8CA-4833-A6F5-CED4025F5F1C Q36416282-63797E8D-91C3-4175-9CD4-5EDDD7FB536B Q36456106-CC40B29A-6D3F-4BEF-92D2-4B89D3E68604 Q36553872-C956D99D-ED9B-4B1C-9099-38AB0DA1CB71 Q36581642-74E601B0-0F79-452F-BB70-6CAFCF1EC6C4 Q36588574-20C594DA-2DF3-4A0D-8138-0B8C250C8454 Q37237804-0AE79172-7BC7-4A80-92AA-A4A9D8703344 Q38031421-42E47223-C153-44DF-8F93-B8C6D6F9A675 Q38113752-38ECF06A-B069-44C9-B77A-DA2A628A5419 Q38197938-CB165592-08E8-43D9-A8E8-45C117A45FE6 Q38997162-099F428B-8A28-4903-9661-9C67319C6395 Q39132122-DE1ABD95-1311-4E1E-8A49-BB17609A64A8 Q49606173-F3538E90-63DE-44F5-B6A6-8E5F74581E38 Q52655109-F8932F26-292F-4DC2-9E4F-C254629C1E11 Q57091632-80966E86-9EFD-4459-B818-616499D13009 Q57165768-5F80E726-42F9-4498-8868-7168D1AA4F9E Q57643835-6507768B-5A08-41B6-8436-1BAAE331FA56 Q58790015-8A49A325-174D-40B8-A6D4-4978A49C4413

P2860

Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.

http://www.wikidata.org/entity/Q34694716

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@ast

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@en

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@nl

type

label

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@ast

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@en

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@nl

prefLabel

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@ast

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@en

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@nl

P1433

Q34694716-FFD250AB-2F7A-4D91-B31D-2084CFD651DA

P1476

Q34694716-11A89E4C-17CD-409C-92E7-476EFD8F034B

P2093

Q34694716-038FF29B-FEC3-4C1A-B095-5407FEA9CDD2

Q34694716-060C1603-00B6-4F82-AF1F-C1E9CFF98FFF

Q34694716-31EB70A1-CF32-442F-AE04-A2FC717BD0DF

Q34694716-4663E0F3-5FA9-459D-84D0-9C604D046979

Q34694716-5975A28D-4345-429C-A61A-19104E82BC90

Q34694716-8B68771A-9A8E-40A2-88D0-9D7FB5CEB0A2

Q34694716-99C90360-4A0F-4925-AD37-2240B6E5606E

P2860

Q34694716-00F1320D-70A2-4756-9A9C-939233D97993

Q34694716-06F4BAAF-DB88-4D8C-A7AC-C5C127AD3BDB

Q34694716-0A5B5EB9-27ED-495A-BB16-80CDA1DC23B6

Q34694716-0D4A4952-4606-459F-95A2-77453F908734

Q34694716-130D4E34-23B1-4CB0-AC7E-6ED6DB7D182B

Q34694716-1CAB5F69-59AC-44B7-BD49-506BD4BD4049

Q34694716-41B85598-8116-40AD-893C-218C306303F8

Q34694716-4B8FF636-3B07-4DEB-9E2B-0D6D722F158E

Q34694716-4D846C46-A5C8-4FA5-9C51-27ED6634F618

Q34694716-5010F284-CB5F-461C-ACDF-895F9C294E78

P2888

Q34694716-C7CE91E8-E007-45AF-B568-9DDD9580F70A

P304

Q34694716-1852A92D-67CB-4A1A-8FB2-17D3DE69ECC8

P31

Q34694716-CF71C488-A133-44F2-AFFE-AF1145FA34FF

P356

Q34694716-1762B075-332D-46B5-8FBB-70A34B7F9397

P433

Q34694716-3CF791A0-F7EA-4577-A543-92744891379D

P478

Q34694716-816BDE2E-F6E4-47E4-A61B-AD9033E9F134

P577

Q34694716-001D9698-D61F-4FAD-B500-FE15E1BCB296

P5875

Q34694716-942B4646-7767-4DB6-8CE4-A508C7B3970A

P6179

Q34694716-00F76B54-3D36-4F6A-A875-6443CE90E298

P698

Q34694716-5A33346B-B3FB-4C7D-BE85-93D676C14665

P932

Q34694716-43E11FEA-1AC9-42A5-A022-F6B3C63C3C47

P356

P1433

European Journal of Human Genetics

P1476

Prevalence of CDKN2A mutations ...... ations for genetic counseling.

@en

P2093

Eric D Wieben

http://www.w3.org/2001/XMLSchema#string

Gloria M Petersen

http://www.w3.org/2001/XMLSchema#string

Hugues Sicotte

http://www.w3.org/2001/XMLSchema#string

Kari G Rabe

http://www.w3.org/2001/XMLSchema#string

Katrina S Pedersen

http://www.w3.org/2001/XMLSchema#string

Robert R McWilliams

http://www.w3.org/2001/XMLSchema#string

Yanhong Wu

http://www.w3.org/2001/XMLSchema#string

P2860

PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing

Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.

Germline p16 mutations in familial melanoma.

Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.

Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.

Prospective risk of cancer in CDKN2A germline mutation carriers

A common variant of CDKN2A (p16) predisposes to breast cancer.

CDKN2A mutations and melanoma risk in the Icelandic population.

Clinical germline genetic testing for melanoma.

Selection criteria for genetic assessment of patients with familial melanoma

P2888

P304

472-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EJHG.2010.198

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49676661

http://www.w3.org/2001/XMLSchema#string

P6179

1018225761

http://www.w3.org/2001/XMLSchema#string

P698

21150883

http://www.w3.org/2001/XMLSchema#string

P932

3060321

http://www.w3.org/2001/XMLSchema#string